tisagenlecleucel
FDA Eliminates REMS for 6 CAR T-Cell Immunotherapies
The FDA announced it has eliminated the Risk Evaluation and Mitigation Strategies (REMS) for six currently approved ...
JULY 8, 2025
FDA Approves Tisagenlecleucel for Relapsed or Refractory FL
The FDA has granted accelerated approval for tisagenlecleucel (Kymriah, Novartis) for the treatment of adult ...
JUNE 3, 2022
CAR-T Therapy Associated With Frequent Reports of Cardiopulmonary AEs
Chimeric antigen receptor T-cell therapy—genetically engineered immune cells programmed to identify tumor ...
JANUARY 28, 2022
ALL Has Potential to Relapse After CAR T-Cell Therapy
B-cell acute lymphoblastic leukemia can recur when leukemic cells become resistant to chimeric antigen receptor ...
OCTOBER 26, 2018
CAR T Rx Kymriah Gains Expanded Approval for Some Large B-Cell Lymphomas
The FDA has granted tisagenlecleucel (Kymriah, Novartis) its second indication—the treatment of adults with ...
MAY 4, 2018
Nathan Singh, MD, and David Porter, MD: How I Manage CAR T-Cell Therapy
The human immune system has powerful potential to fight cancer, mediated in large part by T lymphocytes. Autologous ...
FEBRUARY 28, 2018
CAR-T Therapy Kymriah Granted FDA Approval
The FDA has approved the first CAR-T therapy, tisagenlecleucel (Kymriah, Novartis), for the treatment of patients ...
AUGUST 31, 2017